High mortality in invasive aspergillosis: What we need to know for determination of poor prognosis and next countermeasures

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1185-1187

  Kohno, Shigeru ^a,b  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BETA GLUCOSIDASE; CORTICOSTEROID; ECHINOCANDIN; GALACTOMANNAN; IMMUNOSUPPRESSIVE AGENT; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS; BLOOD SAMPLING; CELL COUNT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HEMATOLOGIC DISEASE; IMMUNE DEFICIENCY; KIDNEY DISEASE; LUNG LAVAGE; LUNG LESION; MICROBIOLOGY; MONOCYTE; MORTALITY; NOTE; ORGAN TRANSPLANTATION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 53349120792     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592256     Document Type: Note

References (11)

1. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
2. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
3. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5:609-22.
4. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205.
5. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44:373-9.
6. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47:1176-84 (in this issue).
7. von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62:341-7.
8. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:696-709.
9. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
10. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97.
11. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.